GLP 1

GLP-1 is a hormone your body makes naturally after you eat. Its full name is glucagon like peptide-1. You don't need to memorize that. What matters is what it does: it helps control your blood sugar, slows down digestion, and tells your brain you are full.

If you have been seeing drug names like Ozempic, Wegovy, Mounjaro, or Trulicity in the news, those are all medications built around this one hormone. They are called GLP-1 receptor agonists, and they have become some of the most prescribed drugs in world for type 2 diabetes and weight management.

What does GLP stand for?

GLP stands for glucagon-like peptide. The "1" just means it was the first of two similar peptides discovered in same gene. There is also a GLP 2, but it works on your gut lining rather than on blood sugar.

The name comes from fact that GLP-1 is encoded inside same gene as glucagon, a hormone that raises blood sugar. Scientists found this in early 1980s when they sequenced the proglucagon gene and realized it actually produces three separate hormones, not just one. GLP-1 was one of those unexpected discoveries. By 1987, three independent research teams had confirmed that a specific fragment called GLP-1(7-37) could directly stimulate insulin release from pancreas.

So in simple terms: glucagon raises your blood sugar, and GLP-1 helps lower it. They come from the same gene but do opposite jobs.

Where does GLP-1 come from in your body?

Your gut produces most of it. Specifically, L-cells in lining of your small intestine and colon release GLP-1 within minutes of eating. The food itself triggers the release, particularly carbohydrates and fats.

But L-cells are not only source. Your pancreas also makes small amounts of GLP-1 from alpha cells. And neurons in nucleus of solitary tract, a region in your brainstem, produce GLP-1 as well. That brain-based production is part of why GLP-1 has such strong effects on appetite and satiety. It is not just a gut hormone. It is a gut-brain hormone.

How does GLP-1 work inside your body?

Once released, GLP-1 does several things at once. Think of it as a coordinator that manages your body's response to food across multiple systems.

First, it goes to your pancreas and tells beta cells to release insulin. Insulin is hormone that moves sugar from your blood into your cells, where it gets used for energy. But GLP-1 only triggers insulin when blood sugar is actually elevated. This is called glucose-dependent insulin secretion, and it is one of the reasons GLP-1 drugs carry a lower risk of hypoglycemia compared to some older diabetes medications.

Second, GLP-1 tells your pancreatic alpha cells to stop producing glucagon. Glucagon normally raises blood sugar by telling your liver to release stored glucose. When GLP-1 suppresses glucagon, less sugar enters your bloodstream.

Third, GLP-1 slows gastric emptying. Food moves out of your stomach more slowly, which means sugar enters your blood more gradually after meals. It also means you feel full for longer.

Fourth, GLP-1 acts on the hypothalamus,  part of your brain that regulates hunger and satiety. It reduces appetite directly at neurological level. This is not just "feeling full from a slow stomach." It is your brain genuinely receiving a signal that says you have had enough.

And there is a fifth effect that gets less attention but matters a lot for long-term health. GLP-1 appears to protect pancreatic beta cells from dying and may even encourage them to grow. In type 2 diabetes, beta cells gradually wear out and lose their ability to produce insulin. GLP-1 may slow that decline.

Why doesn't natural GLP-1 do enough on its own?

Because your body destroys it almost immediately. An enzyme called dipeptidyl peptidase-4, or DPP-4, chops GLP-1 into inactive fragments within about two minutes of it being released. That is not a typo. Two minutes.

For a healthy person, that brief burst is enough to help manage a normal meal. But for someone with type 2 diabetes, the incretin effect (the boost in insulin that comes from gut hormones after eating) is blunted or absent. Their body either makes less GLP-1, responds to it less effectively, or both. Two minutes of a weakened signal is simply not enough.

That is why GLP-1 medications exist. They are engineered to resist DPP-4, so hormone signal lasts for hours or days instead of disappearing in seconds.

How do GLP-1 drugs work differently from natural hormone?

GLP-1 drugs are synthetic peptides designed to activate same receptor as natural GLP-1. But their molecular structure has been modified so DPP-4 cannot break them down easily.

The result is a much longer, much stronger version of what your body was already trying to do. More insulin when blood sugar is high. Less glucagon. Slower digestion. Reduced appetite. And all of it sustained over a clinically meaningful period rather than vanishing in two minutes.

Different drugs achieve this in different ways. Some attach to albumin (a protein in your blood) so they circulate longer. Some use fatty acid chains that slow absorption from injection site. The specific engineering varies, but  principle is same: extend life of GLP-1 so it can actually do its job.

Beyond blood sugar and appetite, GLP-1 drugs have shown benefits that researchers did not initially expect. They can improve cardiac output, coronary blood flow, and left ventricular function. They lower blood pressure and cholesterol. And they reduce risk of major cardiovascular events like heart attacks and strokes. These effects happen because GLP-1 receptors exist on cells throughout your body, not just in pancreas and gut.

Which drugs are GLP-1 receptor agonists?

Several FDA-approved medications fall into this class. They differ in how they are taken, how often, and what they are approved to treat, but they all work by activating the GLP-1 receptor.

Is Ozempic a GLP-1? Yes. Ozempic contains semaglutide and is approved for type 2 diabetes. It is given as a weekly injection. The same active ingredient at a higher dose is sold as Wegovy, which is approved for chronic weight management.

Is Mounjaro a GLP-1? Mounjaro contains tirzepatide, which is technically a dual agonist. It activates both GLP-1 receptor and GIP receptor (glucose-dependent insulinotropic polypeptide). So it is a GLP-1 drug, but it does more than just GLP-1 activation. It is FDA-approved for type 2 diabetes. The same compound at a higher dose is sold as Zepboundfor weight management.

Is Wegovy a GLP-1? Yes. Wegovy is semaglutide at a higher dose than Ozempic, specifically approved for weight loss in adults with a BMI of 30 or higher, or 27 with a weight-related condition.

Is tirzepatide a GLP-1? Partially. Tirzepatide activates GLP-1 receptors, but it also activates GIP receptors. Researchers call it a dual incretin agonist. A 2024 review notes that dual agonists targeting both GLP-1 and GIP have outperformed single-target GLP-1 drugs in clinical trials for both blood sugar reduction and weight loss.

Is Trulicity a GLP-1? Yes. Trulicity contains dulaglutide, a weekly injectable GLP-1 receptor agonist approved for type 2 diabetes. It has also demonstrated cardiovascular benefits in clinical trials.

Is metformin a GLP-1? No. Metformin is a completely different class of drug. It works by reducing glucose production in liver and improving insulin sensitivity in muscle tissue. It does not activate GLP-1 receptor. Metformin is still first-line treatment for type 2 diabetes according to the American Diabetes Association, and GLP-1 drugs are typically added when metformin alone is not enough.

There are also older GLP-1 drugs. Exenatide (Byetta and Bydureon) was first in class, approved in 2005. Liraglutide (Victoza for diabetes, Saxenda for weight loss) is a daily injectable. And oral semaglutide (Rybelsus) is first GLP-1 drug available as a daily pill.

What benefits do GLP-1 drugs offer beyond blood sugar?

This is where the research has gotten really interesting in recent years. Because GLP-1 receptors are spread across so many organ systems, these drugs are showing effects that go well beyond their original diabetes indication.

For heart, GLP-1 receptor agonists have reduced risk of major cardiovascular events including heart attacks and strokes. Three drugs in class, liraglutide, injectable semaglutide, and dulaglutide, carry specific cardiovascular benefit data. The ADA now recommends GLP-1 drugs for people with diabetes who also have atherosclerotic cardiovascular disease.

For brain, GLP-1 receptors are active in regions involved in memory, learning, and neuroprotection. Researchers have found that GLP-1 drugs can cross blood brain barrier and may help slow progression of neurodegenerative diseases like Alzheimer's and Parkinson's. Animal studies show reduced brain inflammation and improved cognitive function. Human trials are still ongoing.

For kidneys, there is growing evidence that GLP-1 drugs may help slow the progression of chronic kidney disease, a common complication of diabetes.

For  liver, semaglutide has shown reductions in liver fat in patients with non-alcoholic fatty liver disease.

For joints and inflammation, early research suggests potential benefits in osteoarthritis and rheumatoid arthritis through anti-inflammatory pathways linked to GLP-1 receptor activation.

None of these are currently FDA-approved uses. But they help explain why GLP-1 drugs are generating so much research interest across so many medical specialties right now.

What is difference between GLP-1 drugs and GLP-1 itself?

The difference is duration and intensity. Natural GLP-1 lasts about two minutes and works at low concentrations. GLP-1 drugs last hours to days and work at pharmacological concentrations. They activate same receptor, but drug version holds on longer and hits harder.

It is a bit like difference between a quick tap on brakes and steady, sustained braking. Both slow car down, but one gives you much more control over a longer distance.

The structural backbone also differs depending on the drug. Some GLP-1 medications are built on actual human GLP-1 molecule (liraglutide, dulaglutide, semaglutide). Others are built on exendin-4, a peptide found in Gila monster saliva that naturally resists DPP-4 (exenatide). And tirzepatide is its own hybrid, activating two receptors at once.

Conclusion

If you are exploring whether a GLP-1 medication might be right for you, the best starting point is a conversation with your doctor. They can look at your HbA1c levels, your weight history, your cardiovascular risk, and any other conditions to help decide which drug, which dose, and which timeline makes sense.

These medications are powerful. But they are not standalone solutions. They work best alongside dietary changes, regular movement, and consistent follow-up with your care team.